Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | What are the drivers of leukemia?

Omar Abdel-Wahab • 12 Oct 2017
ESH 2017
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia

Mutations can change the function of a protein and thus be the driver of diseases. In this video, Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses mutations in RNA splicing factors that have been identified in patients with leukemia, highlighting these exciting new therapeutic targets. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).

More from Omar Abdel-Wahab

1:20
The spliceosome mutations that can cause hematological malignancies
Omar Abdel-Wahab • 5 Oct 2017
0:53
The importance of collaboration in AML research
Omar Abdel-Wahab • 10 Oct 2017
1:14
Neomorphic mutations driving hematological cancers
Omar Abdel-Wahab • 10 Oct 2017
0:52
Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab • 10 Oct 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals